EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

How I treat refractory/relapsed diffuse large B‐cell lymphomas with CD19 ‐directed chimeric antigen receptor T cells

Arnon Nagler iD, Vincenzo Maria Perriello iD, Lorenza Falini, Brunangelo Falini iD

British Journal of Haematology · 2023

DOI: 10.1111/bjh.18724 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Arnon Nagler und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Sheba Medical Center, Tel Hashomer, Israel. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) T cells targeting CD19 represent a promising salvage immunotherapy for relapsed/refractory diffuse large B‐cell lymphoma (R/R DLBCL), offering ~40% of long‐term responses. In everyday clinical practice, haematologists involved in CAR T cell treatment of patients with R/R DLBCL have to deal with diagnostically complex cases and difficult therapeutic choices. The availability of novel immunotherapeutic agents for R/R DLBCL and recent advances in understanding CAR T‐cell failure mechanisms demand a rational approach to identify the best choice for bridging therapy and managing post‐CAR T‐cell therapy relapses. Moreover, positron emission tomography/computerised tomography may result in false‐positive interpretation, highlighting the importance of post‐treatment biopsy. In this review, we discuss all above issues, presenting four instructive cases, with the aim to provide criteria and new perspectives for CAR T‐cell treatment of DLBCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenLymphoma, Large B-Cell, DiffuseHumansReceptors, Antigen, T-CellNeoplasm Recurrence, LocalT-LymphocytesImmunotherapy, AdoptiveAntigens, CD19

Stichwörter der Autor:innen

CD19Chimeric antigen receptor (CAR) T cellscytokine release syndrome (CRS)immune effector cell-associated neurotoxicity syndrome (ICANS)immunohistochemistrylymphomamonoclonal antibodies

Substanzen

Receptors, Chimeric AntigenReceptors, Antigen, T-CellAntigens, CD19

Autor:innen und Institutionen

  • Division of Hematology, Sheba Medical Center, Tel Hashomer, Israel.
  • Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria della Misericordia Hospital, Perugia, Italy.

ORCID-Profile: Arnon Nagler, Vincenzo Maria Perriello, Brunangelo Falini

Zitieren

APA

Nagler, A., Perriello, V. M., Falini, L., & Falini, B. (2023). How I treat refractory/relapsed diffuse large B‐cell lymphomas with CD19 ‐directed chimeric antigen receptor T cells. British Journal of Haematology. https://doi.org/10.1111/bjh.18724

Vancouver

Nagler A, Perriello VM, Falini L, Falini B. How I treat refractory/relapsed diffuse large B‐cell lymphomas with CD19 ‐directed chimeric antigen receptor T cells. British Journal of Haematology. 2023. doi:10.1111/bjh.18724

BibTeX
@article{Nagler2023,
  author = {Nagler, Arnon and Perriello, Vincenzo Maria and Falini, Lorenza and Falini, Brunangelo},
  title = {How I treat refractory/relapsed diffuse large B‐cell lymphomas with CD19 ‐directed chimeric antigen receptor T cells},
  journal = {British Journal of Haematology},
  year = {2023},
  doi = {10.1111/bjh.18724}
}
Kostenlos starten →